You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Medtronic
Mallinckrodt
McKesson
Boehringer Ingelheim

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Patent: 9,441,274

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,441,274
Title:In vitro method and kit for prognosis or prediction of response by patients with rheumatoid arthritis to treatment with TNF-.alpha.factor blocking agents
Abstract: In vitro method and kit for prognosis or prediction of the response of rheumatoid patients to treatment with TNF-.alpha. factor blocking agents, which comprises determining, in a blood sample from said patients, the expression level of at least one of the eight genes selected from the group: HLA-DRB3, EAT2, GNLY, CAMP, SLC2A3, IL2RB, MXD4 and TLR5 or combinations thereof and comparing said expression level to the expression values obtained from responsive and non-responsive patients who showed responsiveness to the treatment and those who showed non-responsiveness thereto.
Inventor(s): Marsal Barril; Sara (Barcelona, ES), Julia Cano; Antonio (Barcelona, ES)
Assignee: FUNDACIO INSTITUT DE RECERCA DE L\'HOSPITAL UNIVERSITARI VALL D\'HEBRON (Barcelona, ES)
Application Number:13/120,445
Patent Claims:see list of patent claims

Details for Patent 9,441,274

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial FUNDACIO INSTITUT DE RECERCA DE L\'HOSPITAL UNIVERSITARI VALL D\'HEBRON (Barcelona, ES) 2028-09-24 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial FUNDACIO INSTITUT DE RECERCA DE L\'HOSPITAL UNIVERSITARI VALL D\'HEBRON (Barcelona, ES) 2028-09-24 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial FUNDACIO INSTITUT DE RECERCA DE L\'HOSPITAL UNIVERSITARI VALL D\'HEBRON (Barcelona, ES) 2028-09-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Baxter
McKesson
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.